Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Praxis Precision Medicines stock in Canada | $42.61

Own Praxis Precision Medicines shares in just a few minutes.

Posted

Fact checked

Praxis Precision Medicines, Inc is a biotechnology business based in the US. Praxis Precision Medicines shares (PRAX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $42.61 – an increase of 1.55% over the previous week. Praxis Precision Medicines employs 50 staff and has a market cap (total outstanding shares value) of $1.7 billion.

How to buy shares in Praxis Precision Medicines

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: PRAX in this case.
  5. Research Praxis Precision Medicines shares. The platform should provide the latest information available.
  6. Buy your Praxis Precision Medicines shares. It's that simple.

Praxis Precision Medicines share price

Use our graph to track the performance of PRAX stocks over time.

Praxis Precision Medicines shares at a glance

Information last updated 2020-12-02.
Latest market close$42.61
52-week range$19 - $46.71
50-day moving average $33.4859
200-day moving average $33.4859
Wall St. target price$57
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Compare online trading platforms

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get a $25 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, IPOs, Precious Metals
$4.95 - $9.95
$9.95 + $1 per contract
$0
Free
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Interactive Brokers
Stocks, Bonds, Options, Mutual Funds, ETFs, Currencies, Futures, Precious Metals
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are equal to or greater than US$10.00)
Min. $1.00, Max. 0.5% of trade value
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
loading

Compare up to 4 providers

Name Product Minimum deposit to invest Funding methods Management fee Available asset types
Wealthsimple Invest
$1
Direct deposit, Bank transfer
0.40% - 0.50%
Stocks, Bonds, ETFs, Commodities
Get a $50 bonus when you open and fund your first Wealthsimple Invest account with a minimum initial deposit of at least $500. Trade and Cash accounts are not eligible.
CI Direct Investing (formerly WealthBar)
$1,000
Direct deposit, Bank transfer
0.35% - 0.60%
Mutual Funds, ETFs
CI Direct Investing offers access to an exclusive and personalized investment portfolio. Get up to $10,000 managed free for a year when you sign up for your first CI Direct Investing account and fund your account.
Justwealth
$5,000
Direct deposit, Bank transfer, Automatic bank withdrawals
0.50%
ETFs
Receive a cash bonus of $50.00-$225.00 when you open a new Justwealth account. RESP accounts require no minimum deposit to begin investing.
Moka
$0
Automatic bank withdrawals
$3/month
ETFs
The Moka app rounds up every purchase you make to the nearest dollar and invests the spare change into low-cost exchange-traded funds (ETFs).
loading

Compare up to 4 providers

Name Product Minimum Opening Deposit Commission Available Markets Platforms
Forex.com
US$100
Minimum US$25
Forex
Metals
Commodities
Indices
Shares
Forex.com Desktop, Forex.com Web Trading, Forex.com Mobile Trading, MetaTrader 4
CFDs are leveraged products which involves greater risk than using cash resources only. You could lose all or more of your initial investment. Trade 80+ currency pairs and 220+ CFDs in equities, commodities and indices on Forex.com.
loading

Compare up to 4 providers

Is it a good time to buy Praxis Precision Medicines stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Praxis Precision Medicines price performance over time

Historical closes compared with the last close of $42.61

1 week (2021-01-07) -29.22%
1 month (2020-12-16) -2.81%
3 months (2020-10-16) 53.27%

Praxis Precision Medicines financials

Gross profit TTM USD$0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation USD$1.7 billion

TTM: trailing 12 months

How to short and sell Praxis Precision Medicines shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "PRAX.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 1.1 million Praxis Precision Medicines shares held short by investors – that's known as Praxis Precision Medicines's "short interest". This figure is 103.4% up from 543,282 last month.

There are a few different ways that this level of interest in shorting Praxis Precision Medicines shares can be evaluated.

Praxis Precision Medicines's "short interest ratio" (SIR)

Praxis Precision Medicines's "short interest ratio" (SIR) is the quantity of Praxis Precision Medicines shares currently shorted divided by the average quantity of Praxis Precision Medicines shares traded daily (recently around 476404.74137931). Praxis Precision Medicines's SIR currently stands at 2.32. In other words for every 100,000 Praxis Precision Medicines shares traded daily on the market, roughly 2320 shares are currently held short.

However Praxis Precision Medicines's short interest can also be evaluated against the total number of Praxis Precision Medicines shares, or, against the total number of tradable Praxis Precision Medicines shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Praxis Precision Medicines's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Praxis Precision Medicines shares in existence, roughly 30 shares are currently held short) or 0.0416% of the tradable shares (for every 100,000 tradable Praxis Precision Medicines shares, roughly 42 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Praxis Precision Medicines.

Find out more about how you can short Praxis Precision Medicines stock.

Praxis Precision Medicines share dividends

We're not expecting Praxis Precision Medicines to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Praxis Precision Medicines overview

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Go to site